22 July 2021
Today, the LEO Foundation and Nordic Capital announce closing of partnership deal to further support LEO Pharma’s ambitious growth strategy and strengthen its position in medical dermatology.
The transaction between the LEO Foundation and Nordic Capital, announced on 23 March 2021, has been formally closed. Nordic Capital invests EUR 450 million in LEO Pharma and becomes a minority shareholder and partner to the LEO Foundation, who will remain the company’s controlling owner.
“We are excited to close the deal and begin a new chapter in the history of LEO Pharma. With the LEO Foundation as the company’s long-term controlling owner and Nordic Capital as co-owner and partner we provide the company with the best possible platform for future growth and success. We are confident that this new ownership structure will further support the realization of the considerable potential of LEO Pharma – and we look very much forward to partnering with Nordic Capital,” said Jesper Mailind, CEO of the LEO Foundation.
Nordic Capital is one of the most active and experienced investors in healthcare globally. The firm has a strong track record of investing in innovative companies and building industry leaders in close partnership with management teams and co-owners. Since inception in 1989, Nordic Capital has invested more than EUR 7 billion in 29 healthcare investments across Europe and North America. Within pharmaceuticals, Nordic Capital’s current and previous investments include Advanz Pharma, Acino, Nycomed, Fougera, Biovitrum and Meda. Today, Nordic Capital has 14 portfolio companies in the broader healthcare sector with c. 44,000 employees and aggregate revenues in excess of EUR 6 bn.
About the LEO Foundation
The LEO Foundation is one of Denmark’s largest commercial foundations and an engaged owner of the pharmaceutical company LEO Pharma. The Foundation’s main objective is to ensure the company’s long-term development and success as a global leader in dermatology, delivering outstanding results. Besides the ownership, the Foundation provides philanthropic grants with the aim to support the best international research in skin diseases and make Denmark a global beacon for skin research.
The Foundation manages financial assets of around DKK 16bn.These assets are invested with the main objectives of ensuring the continued capability to support LEO Pharma’s long-term development and provide funds for philanthropic activities.
About Nordic Capital
Nordic Capital is a leading private equity investor with a resolute commitment to creating stronger, sustainable businesses through operational improvement and transformative growth. Nordic Capital focuses on selected regions and sectors where it has deep experience and a long history. Focus sectors are Healthcare, Technology & Payments, Financial Services, and selectively, Industrial & Business Services. Key regions are Europe and globally for Healthcare and Technology & Payments investments. Since inception in 1989, Nordic Capital has invested more than EUR 17 billion in close to 120 investments. Nordic Capital Advisors have local offices in Sweden, Denmark, Finland, Norway, Germany, the U.K. and the U.S.
Footnote: “Nordic Capital” refers to any, or all, Nordic Capital branded funds and vehicles and associated entities. The general partners of Nordic Capital’s funds and vehicles are advised by several non-discretionary sub-advisory entities, any or all of which is referred to as “Nordic Capital Advisors”.
About LEO Pharma
The company is a leader in medical dermatology with a robust R&D pipeline, a wide range of therapies and a pioneering spirit. Founded in 1908, LEO Pharma has devoted decades of research and development to advance the science of dermatology, setting new standards of care for people with skin conditions. LEO Pharma is headquartered in Denmark with a global team of 6,000 people, serving 93 million patients in more than 130 countries.
Head of Communication and Public Affairs
Tel: +45 20 49 68 69